Clinical trial · no report yet · Phase 3

KANDLELIT-007

A Clinical Study of Calderasib (MK-1084) and Other Treatments for Participants With Non-Small Cell Lung Cancer (MK-1084-007/KANDLELIT-007)

NCT07190248 ↗
Recruiting
Merck Sharp & Dohme LLC
Focused

We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.

Preliminary discovery

Commentary in our index that names this trial so far

Podcasts, YouTube videos and X posts we have indexed. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build.

Channel	Found
X threads	3

The trial

ClinicalTrials.gov

Official title: A Phase 3, Randomized, Open-label, Multicenter Clinical Study to Evaluate the Safety and Efficacy of MK-1084 in Combination With Subcutaneous Pembrolizumab and Berahyaluronidase Alfa (MK-3475A) Versus MK-3475A in Combination With Pemetrexed/Platinum (Carboplatin or Cisplatin) Chemotherapy as First-line Treatment of Participants With KRAS G12C-Mutant, Advanced or Metastatic Nonsquamous NSCLC (KANDLELIT-007)
Phase: Phase 3
Status: Recruiting
Conditions: Non-small Cell Lung Cancer
Interventions: Calderasib; Pembrolizumab (+) Berahyaluronidase alfa; Pemetrexed; Cisplatin; Carboplatin
Arms: Calderasib + Pembrolizumab (+) Berahyaluronidase alfa · Experimental
Pembrolizumab (+) Berahyaluronidase alfa + Chemotherapy · Active comparator
Enrollment: 675 (estimated)
Primary outcomes: Progression Free Survival (PFS) in Participants with Programmed Death-Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥1%
Sponsor: Merck Sharp & Dohme LLC
Start: Oct 8, 2025
Primary completion: Dec 7, 2029 (estimated)
Results posted: No
Registry record: NCT07190248 · updated Oct 26, 2026